Source : https://pubmed.ncbi.nlm.nih.gov/41819567/
The rising global prevalence of obesity and its associated health problems necessitate effective intervention strategies. Historically, many anti-obesity medications have been developed and later withdrawn because of unfavorable adverse event...
Review evaluates safety of GLP-1 receptor agonists for obesity, highlighting significant weight-loss and cardiometabolic benefits while addressing adverse events such as retained gastric contents and aspiration, with clinical recommendations for safer use.
In 85 patients undergoing laparoscopic surgery for benign adnexal tumors, higher BMI was linked to increased abdominal wall thickness but did not significantly prolong primary trocar insertion using the open technique. Complication rates were comparable, highlighting the role of surgical experience.
Source : https://pubmed.ncbi.nlm.nih.gov/41769479/
Internal hernia is a recognized late complication of Roux-en-Y gastric bypass (RYGB), often occurring through mesenteric defects at the jejunojejunostomy (JJ) or Petersen's space. While most hernias result from anatomical...
Case report describes rare enteroenteric fistula–induced internal hernia causing small-bowel obstruction years after Roux-en-Y gastric bypass, successfully treated with robotic laparoscopic fistula excision and rapid postoperative recovery.
Did you know? Obesity-related systemic inflammation can reshape the tumor microenvironment and influence the efficacy and toxicity of immune checkpoint inhibitors in lung cancer. Adipokines, body composition metrics, and inflammatory biomarkers may help explain the “obesity paradox” and predict immune-related adverse events, including endocrine toxicities.
Could integrating obesity-related inflammatory biomarkers improve risk stratification and personalization of immunotherapy in lung cancer?
Could integrating obesity-related inflammatory biomarkers improve risk stratification and personalization of immunotherapy in lung cancer?
Source : https://pubmed.ncbi.nlm.nih.gov/41754837/
Introduction : Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use...
This review finds semaglutide maintains a favorable benefit-risk profile, with no confirmed increased cancer risk in humans and emerging cardioprotective effects, including potential mitigation of anticancer therapy–related cardiotoxicity, warranting continued monitoring.